Responses
Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring, and Novel Technologies
2 Quantitation of CD137 and Nectin-4 expression across multiple tumor types to support indication selection for BT7480, a Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™)
Compose a Response to This Article
Other responses
No responses have been published for this article.